Evidence map›Paper›PMID 19681702›Full record

ReviewExpert review of anti-infective therapy2009

Autophagy as an antimicrobial strategy.

Carlos S Subauste

Abstract readReview
In one paragraph

Review in Expert review of anti-infective therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Host autophagy limitsFrontiers in microbiology · 2022
    Article
  5. Review
  6. Autophagy in Negative-Strand RNA Virus Infection.Frontiers in microbiology · 2018
    Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Carlos S SubausteCase Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106, USA. carlos.subauste@case.edu

Funding

Autophagy and Ocular ToxoplasmosisR01EY018341 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI SUBAUSTE, CARLOS S · 2009 to 2024
$5.0M
CD40 Ligand: Therapy for Opportunistic Pathogens and HIVR01AI048406 · NIAID · UNIVERSITY OF CINCINNATI · PI SUBAUSTE, CARLOS S · 2001 to 2004
$1.0M
NEI NIH HHS EY018341NEI NIH HHS R01 EY018341NIAID NIH HHS AI48406NIAID NIH HHS R01 AI048406
6 · The paper itself

Abstract

Autophagy is a process of lysosomal degradation that was originally described as a cellular response to adapt to a lack of nutrients and to enable the elimination of damaged organelles. Autophagy is increasingly recognized as a process that is also involved in innate and adaptive immune responses against pathogens. Studies on the regulation of autophagy have uncovered components of the autophagic cascade that can be manipulated pharmacologically. Approaches to modulate autophagy may result in novel strategies for the treatment and prevention of various infections.

Indexed as

InfectionsSignal TransductionAnimalsAutophagyBacteriaHumansImmune SystemLysosomesMiceMice, Inbred C57BLToxoplasmaViruses

Identifiers

PMID19681702
PMCPMC3280690

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.